Man in suit with blue striped tie.

Paul Ramsay

CEO, Chairman & Co-Founder, CanaQuest Medical Corp

Paul Ramsay is an accomplished executive and entrepreneur with over 30 years of experience in business development, corporate strategy, and innovation leadership across the advanced materials and biopharmaceutical sectors. He is the Co-Founder, Chairman, and CEO of CanaQuest Medical Corp, a clinical-stage company developing cannabinoid-based therapeutics for epilepsy and other neurological disorders.

Since co-founding CanaQuest in 2008, Mr. Ramsay has guided the company through multiple strategic transformations, including its 2018 pivot into neuroscience-driven drug development. Under his leadership, CanaQuest has advanced a proprietary cannabidiol-based drug candidate that engages multiple neurological pathways to enhance efficacy and tolerability. Recognizing the compound’s synergistic therapeutic potential, Mr. Ramsay is named as a co-inventor on several patent applications.

The company’s preclinical research, conducted in collaboration with Western University, has been published in leading peer-reviewed journals, including the European Journal of Neuroscience, Journal of Neuroscience, and International Journal of Molecular Sciences. In studies focused on refractory epilepsy, CanaQuest’s formulation demonstrated 35% greater efficacy than current leading treatments (Ontario Brain Institute data). Supported by former GW Pharma executives and building on the $7.2B success of Epidiolex, CanaQuest is pursuing FDA Orphan Drug Status to secure seven years of market exclusivity.

Before founding CanaQuest, Mr. Ramsay was Co-Founder, CEO, and Vice President of Business Development at Cymat Technologies Ltd. (TSX: CYM), a high-performance materials company specializing in stabilized aluminum foam. He secured global licensing rights from Alcan International Ltd., negotiated a $10 million technology development agreement with Industry Canada’s TPC program, and was instrumental in over $25 million in financing. During his tenure, Cymat achieved a market capitalization exceeding $200 million in 2002. He established collaborations with industry leaders, including Anheuser-Busch, Norsk Hydro, Hostess Frito-Lay, Northern Telecom, AstraZeneca, GlaxoSmithKline, and Ontario Hydro.